Relationship between insulin resistance and C-reactive protein in a patient population treated with second generation antipsychotic medications

International Clinical Psychopharmacology

Volumn 26, Issue 1, 2011, Pages 43-47

  Kim, Sun H ^a   Reaven, Gerald ^a   Lindley, Steven ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

CRP; insulin resistance; metabolic syndrome; obesity; olanzapine; second generation antipsychotics

Indexed keywords

ARIPIPRAZOLE; C REACTIVE PROTEIN; CLOZAPINE; INSULIN; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; BIPOLAR DISORDER; DRUG EFFECT; FEMALE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MENTAL DISORDERS; MIDDLE AGED; OBESITY; RISK; RISK FACTORS;

EID: 78650847826     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3283400cd3     Document Type: Article

References (30)

1. Abbasi F, Farin HM, Lamendola C, McGraw L, McLaughlin T, Reaven GM (2008). Pioglitazone administration decreases cardiovascular disease risk factors in insulin-resistant smokers. Metabolism 57:1108-1114.
2. Akanji AO, Ohaeri JU, Al-Shammri S, Fatania HR (2009). Association of blood levels of C-reactive protein with clinical phenotypes in Arab schizophrenic patients. Psychiatry Res 169:56-61.
3. Baptista T, Davila A, El Fakih Y, Uzcategui E, Rangel NN, Olivares Y, et al. (2007a). Similar frequency of abnormal correlation between serum leptin levels and BMI before and after olanzapine treatment in schizophrenia. Int Clin Psychopharmacol 22:205-211.
4. Baptista T, Sandia I, Lacruz A, Rangel N, de Mendoza S, Beaulieu S, et al. (2007b). Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. Int Clin Psychopharmacol 22:69-76.
5. Bluher M, Fasshauer M, Tonjes A, Kratzsch J, Schon MR, Paschke R (2005). Association of interleukin-6, C-reactive protein, interleukin-10 and adiponec-tin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism. Exp Clin Endocrinol Diabetes 113:534-537.
6. Carrizo E, Fernandez V, Quintero J, Connell L, Rodriguez Z, Mosquera M, et al. (2008). Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives. Schizophr Res 103:83-93.
7. Du Clos TW, Mold C (2004). C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res 30:261-277.
8. Fan X, Pristach C, Liu EY, Freudenreich O, Henderson DC, Goff DC (2007). Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res 149:267-271.
9. Farin HM, Abbasi F, Reaven GM (2006). Body mass index and waist circumference both contribute to differences in insulin-mediated glucose disposal in nondiabetic adults. Am J Clin Nutr 83:47-51.
10. Greenfield MS, Doberne L, Kraemer F, Tobey T, Reaven G (1981). Assessment of insulin resistance with the insulin suppression test and the euglycemic clamp. Diabetes 30:387-392.
11. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. (2005). Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735-2752.
12. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, et al. (2005). Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 62:19-28.
13. Henderson DC, Copeland PM, Borba CP, Daley TB, Nguyen DD, Cagliero E, et al. (2006). Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry 67:789-797.
14. Kim SH, Abbasi F, Reaven GM (2004). Impact of degree of obesity on surrogate estimates of insulin resistance. Diabetes Care 27:1998-2002.
15. Kim SH, Nikolics L, Abbasi F, Lamendola C, Link J, Reaven GM, et al. (2009). Relationship between body mass index and insulin resistance in patients treated with second generation antipsychotic agents. J Psychiatr Res 44:493-498.
16. Lamberti JS, Crilly JF, Maharaj K, Olson D, Wiener K, Dvorin S, et al. (2004). Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs. J Clin Psychiatry 65: 702-706.
17. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419.
19. McLaughlin T, Abbasi F, Lamendola C, Liang L, Reaven G, Schaaf P, et al. (2002). Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 106:2908-2912.
20. Meyer JM, McEvoy JP, Davis VG, Goff DC, Nasrallah HA, Davis SM, et al. (2009). Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol Psychiatry 66:1013-1022.
21. Ndumele CE, Pradhan AD, Ridker PM (2006). Interrelationships between inflammation, C-reactive protein, and insulin resistance. J Cardiometab Syndr 1:190-196.
22. Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, et al. (2002). Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59:337-345.
23. Newcomer JW, Ratner RE, Eriksson JW, Emsley R, Meulien D, Miller F, et al. (2009). A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. J Clin Psychiatry 70:487-499.
24. Pei D, Jones CN, Bhargava R, Chen YD, Reaven GM (1994). Evaluation of octreotide to assess insulin-mediated glucose disposal by the insulin suppression test. Diabetologia 37:843-845.
25. Ridker PM, Buring JE, Cook NR, Rifai N (2003). C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 107:391-397.
26. Sacher J, Mossaheb N, Spindelegger C, Klein N, Geiss-Granadia T, Sauermann R, et al. (2008). Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers. Neuropsychopharmacology 33:1633-1641.
27. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R (2002). Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 159:561-566.
28. Shen SW, Reaven GM, Farquhar JW (1970). Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. J Clin Invest 49:2151-2160.
29. Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K (2008). First-v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 192:406-411.
30. Sowell MO, Mukhopadhyay N, Cavazzoni P, Shankar S, Steinberg HO, Breier A, et al. (2002). Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab 87:2918-2923.